drugset / Trial / NCT01684969

Evidence of Haloperidol Absorption After Topical Administration

NCT01684969

Phase 0 Withdrawn Eric E. Prommer
RandomizedCrossoverTriple-blindTreatment

Summary

This will be a blinded study to compare the absorption of topical haloperidol with placebo

Timeline

Start
2012-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 0.5 mg Intravenous

Indications

No indication recorded.